Cardiovascular News

Go to navigation
Go to content

Stay up-to-date with the latest developments in the world of medicine provided by Current Medicine Group.

Pages
1
2
3
4
5
6
7
8
9
10
Next

- May 7, 2008
- Smoking cessation rapidly reduces vascular mortality risk in women
- May 7, 2008
- Research highlights gender differences in heart disease
- May 7, 2008
- B vitamins fail to reduce CVD in high-risk women
- May 7, 2008
- Inhibitory rTMS may benefit children after stroke
- May 7, 2008
- WAFACS weighs against homocysteine-lowering in women at CVD risk
- May 7, 2008
- High intra-abdominal fat in adolescence increases cardiometabolic risk
- May 7, 2008
- Oxidized LDL-induced aldose reductase activity increased during foam cell formation
- May 7, 2008
- Longer menstrual cycle associated with unfavorable lipid profile
- May 7, 2008
- Portable ultrasound device offers effective PE triage
- May 7, 2008
- rFVIIa effective for complex cardiac surgery bleeding

Pages
1
2
3
4
5
6
7
8
9
10
Next

Page tools

Publication updates

Register for the alert service and receive updates when publications onrosuvastatin are published.

Efficacy

CRESTOR reduces LDL-C by up to 63%

Clinical research

The best surrogate data will translate into the best clinical outcomes seen so far with statin therapy.

CRESTOR is a trademark of the AstraZeneca group of companies.
Rosuvastatin calcium is manufactured underlicensefromShionogi&CO,Ltd,Osaka, Japan